Cycle Slowdown in Jobs Market

See why this sector has potential for massive earnings gains ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in browser "Now that we're entering into a Fed Rate-Cutting Cycle Here in 2024, this could offer biotech the time to shine." Bryan Bottarelli, Founder, The War Room Last week, we had a rash of tech earnings that dominated the release calendar - highlighted by META Platforms Inc. (META) and Amazon.com Inc. (AMZN). This week, biotech will take center stage - with names like Vertex Pharmaceuticals Inc. (VRTX), Amgen Inc. (AMGN), Eli Lilly & Co. (LLY), and Gilead Sciences Inc. (GILD) set to report. Could this offer you a trigger catalyst to play a name such as VanEck Biotech ETF (BBH), which has their top three holdings as Amgen, Vertex, and Gilead? Here's why I believe the answer is "Yes"... Trade AFTER Closing Bell (the Dark Ticker) Now you can trade an exclusive ticker (from 4 to 4:15 p.m.) for the chance at overnight gains as high as 197%. Discover the Dark Ticker for Yourself Last year, the entire biotech sector was a major laggard. For instance, look at these returns.... Biotech: Major Laggard in 2023 SPDR S&P Biotech ETF (XBI) gained only +7.6% in 2023 iShares Biotechnology ETF (IBB) gained only +3.8% in 2023 SPDR S&P Pharmaceuticals ETF (XPH) gained only +1.6% in 2023 As you can see, all of these top biotech funds severely underperformed the S&P 500's gain of +24%. Why? Fed Rate Hikes Since so many biotech firms borrow capital for research and development - when the Fed is aggressively raising rates - money gets expensive - and cash-burning biotech companies get crushed. But guess what? Here in 2024, we're expecting Fed rate cuts. This could be the trigger for biotech to bounce back hard. After a year of under-performance, the VanEck Biotech ETF BBH is now starting to poke above $168. If this can continue, and it stays above this year-long resistance level - that could be an early indication that higher prices are coming. YOUR ACTION PLAN Now that we're entering into a Fed rate-cutting cycle here in 2024, this could offer biotech the time to shine. And with a series of high-profile earnings reports scheduled for this week, now could be the time to start that upside swing. After an under-performance in 2023, I fully expect a stronger 2024 - which is why I'm already starting to get my War Room traders positioned for a big biotech year. If you'd like to join us inside The War Room to trade this biotech resurgence, you're invited to join our elite trading community. Yes! Tell Me More About The War Room Sub-$5 Blue Chip Could Be 2024's Top Performer!?! The question many investors are asking is pretty simple... With overvalued stocks collapsing, what stock can I actually buy that still has a chance to go up? Where are the BIG gains going to come from next? A sub-$5 stock I'm calling The Last Great Value Stock could be it. Click here to see how to unlock this pick - trading for less than $5. MONDAY MARKET MINUTE Another Potential Oil Price Shock: If you connect the 2019 news flow with what's happening now, then it's reasonable to say another big price change is possible. Here's the logic.... Oil prices tend to trade with a "risk premium" - which increases or decreases based on geo-political uncertainty. Back in 2019, Iranian- backed forces attacked assets in the Persian Gulf, which impacted more than half of Saudi Arabia's production. This singular event caused oil prices to spike 10% in one day. If you look at what's happening right now, it appears like a similar playbook is playing out just like it did in 2019. Tracking. Running with the Deerevil: Caterpillar (NYSE: CAT) shares are indicated to hit an all-time high this morning after profits topped expectations - which should also be a signal that strength in John Deere (Nasdaq: DE) is coming as well. We could have a pair-trade in the works. More to come. Delta (NYSE: DAL) Has upside: In the midst of all the Boeing (NYSE: BA) uncertainty, it's worth noting that Delta Airlines is the US airliner with the least exposure to Boeing aircrafts. They're already Wall Street's #1 airline stock, with 96% of analysts raying shares a "buy" - with the average price target around $54.00, which represents 35% upside from current levels. Tech Ready for the Next Level: Based on what we saw last week in the tech sector, its' time to start looking at the next evolution in the technology arch - which leads to GitLab (Nasdaq: GTLB) and Snowflake (NYSE: SNOW) GTLB provides tools to coders - which is critical as AI advances at such a rapid pace. Snowflake is a leading cloud-based data platform - and both names will (in my view) lead the charge for tech going forward. Both names are ones to watch here in early 2024. INSIGHTS YOU MAY HAVE MISSED Did You Make Money During Earnings Week? Biden's Tragic Blunder Good Energy, Great Dividends! Taking a Shot at a Pullback on This Stock Follow Us on Instagram! FACEBOOK YOUTUBE   Monument Traders Alliance, LLC   You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Forgot your password? Click here to reset it. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2024 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.